0M4 Stock Overview
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Mersana Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.50 |
52 Week High | US$8.76 |
52 Week Low | US$0.83 |
Beta | 1.51 |
1 Month Change | -18.05% |
3 Month Change | 47.62% |
1 Year Change | n/a |
3 Year Change | -73.08% |
5 Year Change | -15.27% |
Change since IPO | -70.70% |
Recent News & Updates
Recent updates
Shareholder Returns
0M4 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 3.4% | -1.2% | -0.8% |
1Y | n/a | -15.8% | 1.0% |
Return vs Industry: Insufficient data to determine how 0M4 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 0M4 performed against the German Market.
Price Volatility
0M4 volatility | |
---|---|
0M4 Average Weekly Movement | 12.6% |
Biotechs Industry Average Movement | 4.9% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 9.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0M4's share price has been volatile over the past 3 months.
Volatility Over Time: 0M4's weekly volatility has decreased from 19% to 13% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 123 | Marty Huber | www.mersana.com |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
Mersana Therapeutics, Inc. Fundamentals Summary
0M4 fundamental statistics | |
---|---|
Market cap | €429.28m |
Earnings (TTM) | -€161.58m |
Revenue (TTM) | €34.69m |
12.4x
P/S Ratio-2.7x
P/E RatioIs 0M4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0M4 income statement (TTM) | |
---|---|
Revenue | US$36.86m |
Cost of Revenue | US$148.27m |
Gross Profit | -US$111.41m |
Other Expenses | US$60.26m |
Earnings | -US$171.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.42 |
Gross Margin | -302.30% |
Net Profit Margin | -465.80% |
Debt/Equity Ratio | 68.4% |
How did 0M4 perform over the long term?
See historical performance and comparison